Deals & Cases

Schellenberg Wittmer advised Santhera on exclusive license agreement for Vamorolone

04.01.2022

Schellenberg Wittmer advised Santhera Pharmaceuticals regarding an exclusive license agreement for the Greater China Region with Sperogenix Therapeutics, a China-based company specializing in orphan diseases. Under this agreement, Sperogenix will in-license the drug candidate Vamorolone for Duchenne muscular dystrophy and other rare disease indications for a total consideration of up to USD 124 million, including a double-digit upfront cash compensation and DMD-related US-regulatory milestone payments amounting to a combined USD 20 million, as well as further double-digit royalties on net sales.

Schellenberg Wittmer's team was led by Philipp Groz (Partner IP/Life Sciences) and comprised Prof. Dr. Peter Picht (Of Counsel IP/Life Sciences), Dr. Michael Nordin (Partner Tax), and Marcel Jakob (Partner Corporate/M&A).

 

Stay up to date!

*Required fields

Newsletters & Newsflashes

Monthly selected key topics from our practice areas, sectors and industries, plus newsflashes on recent developments.

Publications

Monthly email with the latest updates and summaries of the Swiss Federal Supreme Court's case law in arbitration matters.
A regular look from a unique M&A perspective at legal changes, economic developments and societal trends in Switzerland.
Regular insights into Swiss and international trends and legal developments in the construction industry.
Concise analysis of key trends in the fast-moving world of corporate governance for board members of Swiss companies.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.